December 6, 2022
MSD said on December 5 that it has applied for an additional indication to be approved for its PD-1 inhibitor Keytruda (pembrolizumab) as a monotherapy for relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL) in Japan. The submission rides...read more